In Brief: Bristol-Myers Squibb Pravachol
Executive Summary
Bristol-Myers Squibb Pravachol: Liver function testing frequency decreased in revised labeling for the HMG-CoA reductase inhibitor pravastatin. Testing at six weeks and semiannual testing in patients with normal test results at 12 weeks is no longer recommended. The changes are based on safety data from the five-year Pravastatin Primary Prevention Study. "Pravachol is the only HMG to receive clearance from FDA for less frequent liver function testing," Bristol said...